The Beat AML Master Clinical Trial marked its tenth anniversary by reporting that rapid genomic analysis within seven days can direct targeted precision therapy and improve overall survival for acute myeloid leukemia patients. The collaborative study reinforced that fast turnaround is a practical enabler for precision treatment selection rather than a theoretical advantage. Beat AML’s approach centers on matching therapies to genomic findings obtained during the early phase of care. The anniversary update consolidates a decade of evidence supporting operational feasibility for broad genomic profiling in routine clinical workflows for AML.